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Background: The open-label extension of the pivotal, 3-year, phase 3 FREEDOM trial evaluates the long-term 
efficacy and safety of denosumab (DMAb) for up to 10 years in postmenopausal women with osteoporosis. 
Objectives: Report results from the first 2 years of the extension, representing up to 5 continuous years of DMAb 
treatment. 
Methods: All women who completed FREEDOM were invited to participate in the extension. During the 
extension, all women receive 60 mg DMAb sc every 6 months and daily calcium and vitamin D. For those given 
DMAb during FREEDOM, the data reflect 5 years of DMAb (long-term group). For those given placebo during 
FREEDOM, the data reflect 2 years of DMAb (de novo group). 
Results: A total of 4550 (70.2%) women who completed FREEDOM enrolled in the extension (2343 long-term; 
2207 de novo). The long-term group had additional 1.9% and 1.7% yearly lumbar spine BMD increases and 0.7% 
and 0.6% yearly total hip BMD increases during the 4th and 5th years of DMAb treatment (all P<0.0001 compared 
with extension baseline). With 5 years of DMAb, the total BMD increase reached 13.7% (lumbar spine) and 7.0% 
(total hip). BMD increases during the first 2 years of DMAb treatment in the de novo group were 7.9% and 4.1% at 
the lumbar spine and total hip (all P<0.0001 compared with extension baseline). Similar rapid and large 
reductions in serum CTX were observed in both groups following DMAb administration, with attenuation at the 
end of the dosing interval, as previously described.
1
 In both groups, yearly incidences of new vertebral and 
nonvertebral fractures were low and below the rates observed in the FREEDOM placebo group. Adverse events 
(AEs) and serious AEs did not increase over 5 years of DMAb treatment. For 2 subjects in the de novo group, an 
oral AE was adjudicated to ONJ. Both cases healed completely and without further complications; one subject 
continues to receive DMAb. There were no atypical femoral fractures. 
Conclusions: Long-term (up to 5 years) DMAb treatment of postmenopausal women with osteoporosis remained 
well-tolerated and continued to significantly decrease serum CTX and increase BMD. 
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